# Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care

> **NCT04062201** · PHASE3 · COMPLETED · sponsor: **Wits Health Consortium (Pty) Ltd** · enrollment: 402 (actual)

## Conditions studied

- Tuberculosis
- Pre-XDR-TB
- Extensively Drug-Resistant Tuberculosis
- Multi Drug Resistant Tuberculosis
- Rifampicin Resistant Tuberculosis

## Interventions

- **DRUG:** Bedaquiline Oral Tablet
- **DRUG:** Linezolid Oral Tablet
- **DRUG:** Delamanid in Oral Dosage Form
- **DRUG:** Clofazimine Oral Product
- **DRUG:** Levofloxacin Oral Tablet
- **DRUG:** Isoniazid Oral Product
- **DRUG:** Ethambutol Oral Product
- **DRUG:** Pyrazinamide Oral Product
- **DRUG:** Linezolid Oral Tablet
- **DRUG:** Clofazimine Oral Product
- **DRUG:** Levofloxacin Oral Tablet

## Key facts

- **NCT ID:** NCT04062201
- **Lead sponsor:** Wits Health Consortium (Pty) Ltd
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-22
- **Primary completion:** 2024-04-15
- **Final completion:** 2024-04-15
- **Target enrollment:** 402 (ACTUAL)
- **Last updated:** 2024-08-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04062201

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04062201, "Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04062201. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*